



**Eva Herrmann**

**Contact**

Eva Herrmann

## Publications (7)

Behrens F, Wassenberg S, Tony H, Rubbert-Roth A, Müller-Ladner U, Lehn A, Krueger K, Kellner H, Herrmann E, Feist E, Burmester G, Backhaus M, Aringer M, Alten R, Rossmannith T, Koehm M, Burkhardt H. Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study). *Rheumatology (Oxford)* 2021; 60:5318–5328.

Beeres M, Vogl T, Jacobi V, Lee C, Gruber-Rouh T, Herrmann E, Bodelle B, Al-Butmeh F, Kerl M, Schulz B, Loch M, Bauer R. Bolus timing in high-pitch CT angiography of the aorta. *Eur J Radiol* 2013; 82:1028–33.

Beeres M, Jacobi V, Vogl T, Zangos S, Bodelle B, Siebenhandl P, Lee C, Gruber-Rouh T, Kerl J, Herrmann E, Mastragelopoulos A, Schell B, Bauer R. High-pitch dual-source CT angiography of the whole aorta without ECG synchronisation: initial experience. *Eur Radiol* 2011; 22:129–37.

Kronenberger B, Hopf U, Pape G, Wursthorn K, Nasser S, Goeser T, Spengler U, Buggisch P, Gerlach T, Hinrichsen H, Herrmann E, Berg T, Zeuzem S. Efficacy of amantadine on quality of life in patients with chronic hepatitis C treated with interferon-alpha and ribavirin: results from a randomized, placebo-controlled, double-blind trial. *European journal of gastroenterology & hepatology* 2007; 19:639–46.

von Wagner M, Herrmann E, Häussinger D, Bernsmeier C, Bergk A, Heintges T, Rasenack J, Hinrichsen H, Berg T, Huber M, Zeuzem S. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. *Gastroenterology* 2005; 129:522–7.

Berg T, Hopf U, Pape G, Wursthorn K, Nasser S, Goeser T, Spengler U, Herrmann E, Buggisch P, Gerlach T, Hinrichsen H, Kronenberger B, Zeuzem S. Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial. *Hepatology (Baltimore, Md.)* 2003; 37:1359–67.

Berg T, Sarrazin C, Herrmann E, Hinrichsen H, Gerlach T, Zchoval R, Wiedenmann B, Hopf U, Zeuzem S. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. *Hepatology (Baltimore, Md.)* 2003; 37:600–9.

## Projects (0)

No results found.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)